It is made available under a CC-BY-ND 4.0 International license .

1 Type of the Paper (Article)

2	Molecular Insights into β -Lactams Resistance in Klebsiella pneumoniae Clinical
3	Isolates with a Focus on Multidrug Resistance and Virulence
4	
5	Lavouisier F.B. Nogueira#, Marília S. Maia#, Marco A.F. Clementino#, Ila F.N. Lima, Jorge L.N.
6	Rodrigues, Luciana V.C. Fragoso, Glairta S. Costa, Jose Q.S. Filho, Alexandre Havt, Deiziane
7	V.S. Costa, Lyvia M.V.C. Magalhães, Dilza Silva, Nicholas E. Sherman, José K. Sousa* and
8	Aldo A.M. Lima*
9	# - These authors contributed equally to this work.
10	* - Corresponding authors.

11 Abstract: Klebsiella pneumoniae is associated with high resistance to antimicrobials and 12 is common in isolates from colonization and healthcare-associated infections (HAIs). 13 This study aims to develop assays to detect resistance genes belonging to the *bla* family 14 and investigate metabolic pathways in resistant isolates of K. pneumoniae. The genes of 15 the subfamilies included were: blaSHV, blaTEM, blaNDM, blaKPC, blaGES, blaCTX-M 16 and relevant variants of the *bla*OXA subfamily. Mass spectrometry data were acquired 17 on the Orbitrap IDX spectrometer (Thermo) connected to the Vanquish UPLC system. 18 Isolates of *K. pneumoniae* (N = 122) were obtained from clinical samples from 04/23/2019 19 to 05/29/2021. A high prevalence of resistance to penicillins, cephalosporins and 20 carbapenems was found among the isolates. The identified genotypic profile showed a 21 high prevalence of genes belonging to Ambler's classes of beta-lactamases A, B and D. 22 In the metabolomic study, the N-fructosyl isoleucine metabolite was identified 23 increased in multidrug-resistant (MDR) strains of K. pneumoniae compared to strains

It is made available under a CC-BY-ND 4.0 International license .

susceptible to antimicrobials. In conclusion, the assays developed were efficient in detecting the main genes of the *bla* family of resistance in *K. pneumoniae*. The use of the pentose phosphate metabolic pathway suggests a beneficial regulation of bacterial growth, and colonization in MDR *K. pneumoniae* strains, with may indicate the use of this pathway as a virulence mechanism in resistant strains.

29 KEYWORDS: Antimicrobial resistance; multidrug-resistant; β-lactamases; qPCR;
 30 molecular diagnosis; *Klebsiella pneumoniae*.

31 INTRODUCTION

Bacterial resistance to antimicrobial agents is a global public health problem that leads to an increase in the cost of treatment, length of stay, morbidity and mortality of hospitalized patients, especially in intensive care units (ICU).^{1,2} In this sense, understanding the emergency mechanisms of regulation and dissemination of resistance to antimicrobial agents in the pathogenesis of bacterial colonization and/or infection can be of critical importance in preventing and controlling this problem.

Klebsiella pneumoniae is a Gram-negative γ-proteobacteria bacteria, belonging to the *Enterobacteriacae* family, and is generally viewed as an opportunistic microorganism, carrying several virulence factors and capable of accumulating resistance genes to various classes of antimicrobials. It is commonly related to cases of colonization and/or healthcare-associated infections (HAIs) and has been identified as an etiological agent in pneumonia, urinary tract infections (UTI), soft tissue and surgical wound infections, bacteremia, and sepsis.³

45 It is estimated that *K. pneumoniae* is responsible for approximately 10% of all 46 cases of HAIs, and of these, 32.8% are caused by strains resistant to multiple

It is made available under a CC-BY-ND 4.0 International license .

47 antimicrobial drugs. However, studies indicate that the rate of isolated strains
48 presenting resistance to antimicrobials has increased over the years.^{4,5}

K. pneumoniae has been associated with the ability to overcome colonization resistance imposed by the gastrointestinal microbiota⁶ and has been reported as an emerging Multidrug-Resistant microorganism of emergency priority by the World Health Organization (WHO) for the development of new therapies.⁷ Epidemiological data have demonstrated that *K. pneumoniae* can translocate from the gastrointestinal tract to other sterile sites of the same host or other patients through the fecal-oral route. What makes clear the clinical relevance of this microorganism.⁸

One of the most likely causes of the increasingly frequent emergence of bacterial strains resistant to one or more antibiotics is the excessive and sometimes incorrect use of antimicrobials. The relatively long time required to identify the pathogen by traditional methods, as well as for the results of the antimicrobial susceptibility test (AST), forces the clinician to use broad-spectrum drugs empirically, increasing selective pressure, which ends up benefiting pathogens genetically capable of adapting to the adverse environment.^{1,9}

Possible answers to reduce the time needed to obtain a resistance profile, and to investigate new approaches in treatment, is the development of molecular methodologies, that can make the identification of resistance faster, and also be more sensitive than the traditional methodologies.¹⁰ And the investigation of metabolic differences between sensitive and resistant strains, that can lead to metabolites or pathways that can be used as targets for the development of new treatments and strategies for dealing with multidrug-resistant (MDR) microorganisms.¹¹⁻¹²

It is made available under a CC-BY-ND 4.0 International license .

70	Beta-lactams are the class of antimicrobials most affected by resistance in
71	general, which is conferred in gram-negatives, mainly by the bla gene family, this
72	group of genes encodes enzymes called beta-lactamases, which can neutralize the
73	action of beta-lactams through hydrolysis of the beta-lactam ring. ^{13–15}

74 In this study it was investigated the phenotype of resistance, the genotypic
75 profile of the *bla* family of β-lactamases, and the metabolic differences between
76 sensitive and MDR *K. pneumoniae* strains, isolated from patients admitted to the ICU in
77 a university hospital in the city of Fortaleza-CE, Brazil.

78 We aim to develop a molecular assay, capable of identifying all variants of the 79 most relevant genes of the bla family, these being: blaSHV, blaTEM, blaNDM, blaKPC, 80 blaGES and blaCTX-M. In addition, also was included the most epidemiologically 81 relevant variants of the *bla*-OXA subfamily. Thus, creating a set of primers capable of 82 detecting the presence of hundreds of resistance genes with a reduced number of 83 reactions. Were also investigated the main differences between the metabolites up and 84 down regulated in sensitive and MDR strains of K. pneumoniae, both from the 85 intracellular medium and the supernatant among themselves and in comparison, with 86 the control medium.

87 RESULTS

Selection of bacterial samples. A total of 249 samples of Gram-negative bacteria resistant to beta lactam antimicrobials were collected from 04/23/2019 to 05/29/2021, those were identified, and the most prevalent microorganism found was *Klebsiella pneumoniae* 48.99% (122/249), been 21,8% from infections cases and 78,2% from colonization cases.

It is made available under a CC-BY-ND 4.0 International license .

93	Identification of the phenotypic profile of beta-lactams resistance of K.
94	pneumoniae strains. The bacteria isolates included in the study were tested against a
95	wide range of beta-lactams drugs, and the presence of a high percentage of isolates
96	resistant to these drugs was verified, which included <u>Penicillins</u> : ampicillin/sulbactam
97	(92.00%) and piperacillin/tazobactam (88.46%), Cephalosporins: cefepime (83.02%),
98	cefoxitin (73.68%), ceftazidime (86.54%), ceftazidime/avibactam (11 .76%), ceftriaxone
99	(83.02%), cefuroxime (90.38%) and cefuroxime axetil (81.82%) and Carbapenems:
100	ertapenem (44.00%), imipenem (71.70%) and meropenem (69.81%), as shown in Figure
101	1.



102

103	Figure 1. Prevalence of <i>K. pneumoniae</i> isolates resistant to the beta-lactams evaluated
104	(Penicillins, Cephalosporins and Carbapenems), demonstrating a phenotypic profile of
105	resistance to multiple beta-lactams drugs, in approximately 70% of the isolates, with
106	the exception of ceftazidime/avibactam and ertapenem.
107	Primers design. After selection on the platforms: Comprehensive Antibiotic
108	Resistance Data-base (CARD) and National Center for Biotechnology and Information
109	(NCBI, USA), and subsequent compilation and analysis of FASTA sequences, it was
110	possible to identify consensus sequences common to all sequences available in the
111	databases for each of the genes included in the study: bla SHV (N = 156), bla TEM (N =
112	167), <i>bla</i> NDM (N = 27), <i>bla</i> KPC (N = 208), <i>bla</i> GES (N = 25), and <i>bla</i> CTX-M (N = 144).
113	Except for the <i>blaOXA</i> gene, for which the most clinically relevant sequences were used

114 (N = 203).

The blaCTX-M and blaOXA genes, due to their diversity and high degree of 115 116 genetic variation between homologous sequences, were grouped into clades, and 117 divided into groups. the blaCTX-M gene group was named according to the 118 international standardization for this gene with the CTX-M 1like been divided into two 119 groups due to its high number or sequences and the genetic variation between them. 120 CTX-M 1.1like (N = 42), CTX-M 1.2like (N = 16), CTX-M 2like (N = 23), CTX-M 8like (N = 14) and CTX-M 9like (N = 49), while the blaOXA gene was divided into the OXA-23like 121 122 (N = 25), OXA-24/40like (N = 8), OXA-48like (N = 17) and OXA-51like (N = 153), as can 123 be seen in **Figures 2** and **3**.

It is made available under a CC-BY-ND 4.0 International license .





Figure 2. Cladogram of the *bla*OXA subfamily showing the most epidemiologically relevant groups, covered by the primers developed, and the percentage of sequences identifiable by each primer in comparison with the total number of the *bla*OXA family (N = 441) at the time of publication of this work.

129

It is made available under a CC-BY-ND 4.0 International license .



130

Figure 3. Cladogram with all sequences from the *bla*CTX-M subfamily divided into groups, illustrating the identifiable sequences, and the percentage of sequences detectable by each primer in comparison with the total number of the *bla*CTX-M family (N = 144) until the time of publication of this work.

A total of 14 pairs of primers were developed, which together have the capacity to detect 929 variants of resistance genes belonging to the *bla* gene family. The primer sequences for genes with conserved and non-conserved sequences can be found in **Tables 1** and **2**, respectively.

139

140

141

142

It is made available under a CC-BY-ND 4.0 International license .

143

Table 1. Primer sequences for conserved genes

Name of	Number of variations	Primer	Sequence I	Primer
gene	detectable	name		size
blaSHV	156	SHV-F	ATTATCTCCCTGTTAGCCACCC	22
		SHV-R	GTTTAATTTGCTCAAGCGGCTG	22
blaTEM	167	TEM-F	ACCCAGAAACGCTGGTGAAA	20
		TEM-R	GGGGCGAAAACTCTCAAGGA	20
blaNDM	27	NDM-F	GAAGCTGAGCACCGCATTAG	20
		NDM-R	CCATTTGCTGGCCAATCGTC	20
blaKPC	208	KPC-F	TCGCGGAACCATTCGCTAAA	20
		KPC-R	GAATGAGCTGCACAGTGGGA	20
blaGES	25	GES-F	GCCCAGGAGAGAGAGATTACGC	20
		GES-R	CTTGACCGACAGAGGCAACT	20

144

145

146 **Table 2.** Primer sequences for non-conserved genes, divided into clades.

N	Name of	Number of	Primer		Primer
gene		variations detectable	name	Sequence	size
	blaCTX-M 1.1like	42	CTXM1.1L-F	GATTGCGGAAAAGCACGTCA	20
blaCTX-M		-	CTXM1.1L-R	TTCATCGCCACGTTATCGCT	20
	blaCTX-M 1.2like	16	CTXM1.2L-F	CGCCGCTGATTCTGGTCA	18
		-	CTXM1.2L-R	TGACGATTTTAGCCGCCGAC	20

It is made available under a CC-BY-ND 4.0 International license .

	blaCTX-M 2like	23	CTXM2L-F	ATGGCGCAGACCCTGAAAAA	20
			CTXM2L-R	CTGCCGGTTTTATCGCCCA	19
	blaCTX-M 8like	14	CTXM8L-F	CGCTCAACACCGCGATCC	18
			CTXM8L-R	ATCCCCGACAACCCACGAT	19
	blaCTX-M 9like	49	CTXM9L-F	CGTGGCTCAAAGGCAATACG	20
			CTXM9L-R	TCTGTTGCGGCTGGGTAAAA	20
	blaOXA-23like	24	OXA23L-F	GCTCTAAGCCGCGCAAATAC	20
			OXA23L-R	TGACCTTTTCTCGCCCTTCC	20
	blaOXA-24/40like	8	OXA24/40L-F	TGCCGATGACCTTGCACATA	20
blaOXA			OXA24/40L-R	CCATTAGCTTGCTCCACCCA	20
	blaOXA-48like	17	OXA48L-F	GGTAGCAAAGGAATGGCAAG	21
			OXA48L-R	GGGCGATCAAGCTATTGGGA	20
	blaOXA-51like	153	OXA51L-F	GATCGGCCTTGAGCACCATA	20
			OXA51L-R	GCCATAACCAACACGCTTCA	20

147

In silico primers validation. The parameters obtained for each primer after
analysis using the Primer-BLAST® (NCBI, USA) and Sequence Manipulation Suite
(SMS): PCR Primer Stats software are available in Table 3.

151 **Table 3.** Parameters obtained by *in silico* validation of the developed primers.

Gene	Primername	Tm (C°)	GC%	Self	Self 3'	Produt
Gene	Timername Tim (C		0070	complementarity	complementarity	length
	SHV-F	59,2	50,0	3	0	
blaSHV						70
	SHV-R	59,3	45,4	5	3	
blaTEM	TEM-F	60,1	50,0	4	0	110

	TEM-R	59,9	55,0	2	1	
hlaNDM	NDM-F	59,3	55,0	5	1	86
	NDM-R	60,1	55,0	6	2	
hlaKPC	KPC-F	60,3	50,0	4	2	128
emiti e	KPC-R	60,3	55,0	5	1	
blaGES	GES-F	59,9	60,0	3	2	94
	GES-R	59,9	55,0	3	2	-
blaCTX-M 1.1like	CTXM1.1L-F	59,7	50,0	4	1	87
	CTXM1.1L-R	60,1	50,0	4	2	-
blaCTX-M 1.2like	CTXM1.2L-F	60,1	61,1	3	2	90
	CTXM1.2L-R	61,0	55,0	3	3	-
blaCTX-M 2like	CTXM2L-F	60,5	50,0	4	0	155
	CTXM2L-R	60,7	57,8	4	1	_
blaCTX-M 8like	CTXM8L-F	61,5	66,6	4	2	197
	CTXM8L-R	60,9	57,8	3	2	
blaCTX-M 9like	CTXM9L-F	59,9	55,0	3	2	180
	CTXM9L-R	60,1	50,0	3	0	-
blaOXA-23like	OXA23L-F	60,0	55,0	4	0	129
	OXA23L-R	59,9	55,0	2	0	
blaOXA-24/40like	OXA24/40L-F	59,7	50,0	4	2	177
	OXA24/40L-R	60,0	55,0	4	0	- 1//
bla OXA-48 like	OXA48L-F	59,8	52,3	3	0	183
	OXA48L-R	59,8	55,0	4	0	_ 100
blaOXA-51like	OXA51L-F	59,8	55,0	4	2	199
	OXA51L-R	59,1	50,0	2	1	

It is made available under a CC-BY-ND 4.0 International license .

152

153	Testing, optimization, and standardization of in vitro reactions. All primers
154	were tested using positive controls developed in house, and it was possible to verify
155	that the ideal annealing temperature (Ta) for the developed primer pairs was $61^{\circ}C$,
156	except for the primer referring to the <i>bla</i> NDM gene, for which the ideal Ta was 64°C.
157	The reactions were then evaluated for their specificity and stability by checking the
158	Melting temperature (Tm). The melting curves are available in the supplementary
159	material Figure S1 .
160	Efficiency curve It was found that all tested primers presented an efficiency
161	rate ≥93.21 and ≤101.28%, R ² ≥0.99, and detection limit between ≈2 and ≈13 copies/µL as

162 shown in **Table 4**.

163

 Table 4. Results of the efficiency curves of the developed primers.

	Efficiency	Correlation	Th	Detection limit	Melting Peak
Gene name	(%)	coefficient (R ²)	Inresnoid	(Copies/µL)	(Tm°C)
blaSHV	96,15	0,992	0,60	≈2	86,7
blaTEM	95,32	1,000	0,70	≈2	81,5
blaNDM	99,90	0,999	0,48	≈2	85,7
blaKPC	100,44	0,992	0,24	≈2	85,7
blaGES	100,21	0,997	0,27	≈2	81,7
blaCTX-M1.1like	95,75	0,999	0,40	≈13	84,3
blaCTX-M1.2like	100,82	0,994	0,32	≈13	83,2
blaCTX-M 2like	98,09	0,998	0,30	≈2	86,4
blaCTX-M 8like	95,32	1,000	0,10	≈13	88,4
blaCTX-M 9like	97,82	0,996	0,10	≈2	89,0

It is made available under a CC-BY-ND 4.0 International license .

blaOXA-23like	99,51	1,000	0,15	≈2	78,4
blaOXA-24/40like	101,82	0,988	0,15	≈13	78,7
blaOXA-48like	93,21	1,000	0,20	≈13	80,29
blaOXA-51like	95,51	0,993	0,55	≈2	82,0

164

Identification of the genetic resistance profile of K. pneumoniae isolates. The 165 166 122 K. pneumoniae isolates were tested against the 14 pairs of primers developed, and it was possible to verify a high prevalence of beta-lactam resistance genes among the 167 168 isolates analyzed. The most prevalent genes detected were, respectively: *bla*KPC 169 (95.90%); blaSHV (94.26%); blaCTX-M 1.2like (88.52%); blaCTX-M 2like (83.61%); blaCTX-170 M 1.1like (80.33%); blaTEM (80.33%); blaNDM (33.61%); blaOXA-23like (28.69%); blaGES 171 (20.49%); blaOXA-51like (15.57%); blaCTX-M 9like (13.93%); blaCTX-M 8like (12.30%); 172 blaOXA-24/40like (11.48%) and blaOXA-48like (3.28%). The results can be seen in Figure 173 **4A**, grouped according to Ambler's classification.

It is important to note that not all variants of each group of genes analyzed belong to a single class in the Ambler's classification, such as *bla*TEM and *bla*SHV genes, where not all variants have activity as extended spectrum beta-lactamases (ESBL) for example, however, due to the grouping of all sequences in a single primer, the separation of these sequences into other groups would be impossible, so the grouping of genes was carried out globally in a way that covered the mains classification of the subfamily in question.

181 Through the data obtained by the qPCR reactions developed, it was also 182 possible to verify that the isolates analyzed during this study had the presence of

It is made available under a CC-BY-ND 4.0 International license .

- 183 several genes belonging to the *bla* family accumulated, with values varying from 3 to
- 184 12 of the tested genes, present per isolate, as shown in **Figure 4B**.



Figure 4. (A) Prevalence of beta-lactams resistance genes among the analyzed isolates,
grouped according to the Ambler classification. (B) The percentage of *K. pneumoniae*isolates showing accumulation of genes encoding beta-lactamases belonging to the *bla*family.

185

190	Comparisons of metabolomic profiles of K. pneumoniae isolates. In total, 241
191	metabolites were identified in positive mode and 116 metabolites identified in negative
192	mode. Among these, 309 metabolites were identified by combining data from both
193	acquisition modes (positive and negative) without redundancy. The principal
194	component analysis (PCAs) and the heatmap analysis between the metabolites in
195	supernatant of susceptible K. pneumoniae versus the control culture medium showed
196	complete separation of the main vectors of the PCA plots and differential upregulation
197	or downregulation between the two experimental groups (Figure 5). Among these
198	metabolites, 25 were upregulated or downregulated. Interestingly, metabolites related
199	to the synthesis of nitrogenous bases, protein synthesis and energy supply to the
200	bacterial cell are significantly increased in supernatant derived from susceptible K.
201	pneumoniae (Figures S2, S3 and S4). Similar findings were detected between MDR K.
202	pneumoniae strains and control culture medium (Figures S5, S6 and S7).



It is made available under a CC-BY-ND 4.0 International license .

Figure 5. Comparison between susceptible *K. pneumoniae* supernatants (Sens) versus culture media. (A) Plot of the principal component analysis (PCAs) and (B) the heatmap of the comparison of metabolites between the supernatant of susceptible *K. pneumoniae* versus the control culture media.

The principal component analysis (PCAs) and the heatmap analysis of metabolites in supernatants from *K. pneumoniae* MDR versus susceptible isolates exhibited complete separation of the main vectors of the PCA plots (**Figure 6A**) and differences on levels of metabolites (**Figure 6B**). The analysis of deregulated metabolites between *K. pneumoniae* MDR versus susceptible isolates showed increased N-fructosyl isoleucine in the MDR *K. pneumoniae* isolates (p < 0.05, **Figure 6C**).



Figure 6. Comparison of supernatants from *K. pneumoniae* MDR versus susceptible (Sens). (A) Plots of the principal component analysis (PCAs) and (B) the heatmap of the comparison of metabolites between the supernatant of *K. pneumoniae* MDR versus

It is made available under a CC-BY-ND 4.0 International license .

218 susceptible (Sens). (C) Plots of dysregulated metabolites between supernatants of K.

- 219 *pneumoniae* MDR and susceptible.
- 220

221 Analysis of the intracellular metabolites of susceptible versus MDR K.

- 222 pneumoniae showed differences in the PCAs vectors (Figure 7A), heatmap (Figure 7B).
- and increased N-fructosyl isoleucine levels in the MDR K. pneumoniae isolates (p<0.05,
- Figure 7C). Figure 8 shows the PCAs and heatmap plots of supernatant from sensitive



and MDR K. pneumoniae.

Figure 7. Comparison of Intracellular media of *K. pneumoniae* MDR versus susceptible (Sens). (A) Principal Component Analysis (PCAs) plots and (B) Heatmap of the Intracellular Environment of *K. pneumoniae* MDR and susceptible. (C) Plots of dysregulated metabolites between the intracellular media of *K. pneumoniae* MDR and susceptible.

It is made available under a CC-BY-ND 4.0 International license .



Figure 8. Comparison of *K. pneumoniae* Multidrug-Resistant (MDR) supernatants versus culture media. (A) Principal component analysis (PCAs) plots and (B) Heatmap of the supernatant of *K. pneumoniae* susceptible and MDR. Observe the separation of the main vectors of the (PCAs) plots and details of the differences in the heatmap between the two experimental groups.

238 DISCUSSION

During the period analyzed in the study, 249 bacterial isolates resistant to two or more classes of antimicrobials used in TSA were identified. Of these resistant isolates, 48.99% (122/249) belonged to the species *Klebsiella pneumoniae*, being this microorganism the most prevalent among those identified.

This data is consistent with what is seen in Egypt, where when evaluating 186 samples from Cairo hospitals, *K. pneumoniae* was found as the main gram-negative bacterial agent representing 40.9% (76/186) of the identified microorganisms, and

It is made available under a CC-BY-ND 4.0 International license .

246 among these isolates obtained, a high prevalence of resistance to beta-lactams, 247 quinolones, and sulfonamides was identified (89.4%, 89.4% and 87.1%) respectively.¹⁶ 248 The phenotypic profile of the K. pneumoniae isolates analyzed in the present 249 study demonstrated high levels of resistance to the beta-lactams drugs tested in all 250 classes evaluated (penicillins, cephalosporins and carbapenems). Although the 251 resistance profile of strains may vary depending on the test location and the conditions 252 to prevent spread, the resistance to beta-lactams among Enterobacteriaceae is known to 253 be high, as demonstrated in a study carried out in Brazil, with samples of human and 254 veterinary origin where 62.85% and 54.28% of Enterobacteriaceae isolated were resistant 255 to amoxicillin/clavulanate and cefazolin respectively.¹⁷

256 In studies carried out in Egypt, evaluating isolates of K. pneumoniae from food 257 sources, and in Tunisia and Iran evaluating isolates from hospital samples, the 258 presence of high resistance to beta-lactams can be verified for ampicillin/sulbactam (95.5%), 259 (93%), (95.5%), ceftazidime cefoxitin cefotaxime (93.2%),260 amoxicillin/clavulanate (86.4%), ertapenem (90.9%) and temocillin (84.0%).^{18, 19, 20}

Likewise, in a study carried out with 102 isolates obtained from two Portuguese hospitals, the presence of resistance rates > 90% was verified for all beta-lactam drugs tested, except for cephalosporins: cefoxitin (40.2%), cefotetan (68.6%) and carbapenems:

264 ertapenem (23.5%), imipenem (32.4%), meropenem (34.3%) and doripenem (33.3%).²¹

This result is consistent with that found in this study, where the beta-lactam drugs that showed a lower resistance rate belonged to the same classes mentioned, namely: cefoxitin (73.68%), ceftazidime/avibactam (11.76%), ertapenem (44.00%), imipenem (71.70%) and meropenem (69.81%).

It is made available under a CC-BY-ND 4.0 International license .

Resistance to beta-lactams is conferred in Gram-negatives mainly by genes belonging to the *bla* family. This group of genes is composed of dozens of subfamilies and hundreds of genetic subvariants in each family, the molecular panel developed managed to encompass some of the most predominant and clinically relevant subfamilies among clinical isolates, identified in several studies, namely: *bla*SHV, *bla*TEM, *bla*NDM, *bla*KPC, *bla*GES, *bla*CTX-M and *bla*OXA.²²⁻²⁴

After analysis using the Primer-BLAST® (NCBI, USA) and Primer Stats Sequence Manipulation Suite (SMS) software, it was verified that the developed primers have specificity for the sequences used in the alignment, melting temperature (Tm) between 59 29 °C and 61.55 °C, GC% concentration varying between 45.45% and 66.67% in addition to having complementary base numbers \leq 6 in the analysis of dimer and hairpin formation. The values obtained for these parameters therefore demonstrate that they are compatible with those obtained in reference studies.^{25–27}

282 Due to the high number of sequences included in the development of primers, 283 many of the alternatives obtained through Primer-BLAST® (NCBI, USA) did not meet 284 the stability requirements regarding the formation of secondary structures (self-285 annealing and hairpins), In order to choose the options with the best performance in 286 relation to these parameters, the GC clamp was relaxed so that the primers SHV-F, 287 SHV-R, CTXM1.2L-R and CTXM2L-R obtained 4 G or C residues within the last 5 288 nucleotides of the 3' end, the primers CTXM9L-R and CTXM2L-F did not present C or 289 G residues within the last 5 nucleotides of the sequence.

This fact could lead to the formation of strong bonds and increase the Tm value in primers with more than 3 terminal GC residues, and cause inhibition of amplification due to the presence of weak bonds when there is an absence of terminal medRxiv preprint doi: https://doi.org/10.1101/2023.12.30.23300671; this version posted September 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

293 CG ^{28,29}. Such changes, however, were not evident when the primers were tested *in*294 *vitro*.

The variety of sequences detectable by the developed primers makes in vitro validation using positive controls for all sequences virtually impossible. In silico analysis allowed the evaluation of all tested sequences quickly, cheaply and constantly, since the developed primers can be tested against new variants of the target genes.²⁶⁻²⁸

In vitro analyzes were carried out using SYBR Green master mix, the melting curve was therefore used as a parameter to evaluate the specificity of the reactions. And it was verified that for all tested primers a single melting peak was found, indicating the formation of a single amplicon. And excluding the presence of secondary structures (primer dimers and hairpins).

The analysis of the melting curve and Tm is considered fundamental to test the specificity of reactions that use SYBR Green as an amplification indicator, because unlike reactions that use specific probes, which emit fluorescence only when the reaction occurs at the expected target. The SYBR Green works by binding to any double-stranded fragment formed, thus emitting fluorescence. Therefore, only by analyzing the melting curve and the specific Tm of the amplicon is it possible to determine whether the reaction was successful.^{29–31}

The efficiency curve and its parameters were used to evaluate the performance of qPCR reactions, by checking how efficiently the targets were amplified in each PCR cycle.^{32, 33} When evaluating the activity of primers in qPCR reactions using the efficiency curve, it was found that all primers analyzed in this study presented efficiency values >90% and <110% and correlation coefficients (R^2) >0.9, thus being in accordance with the parameters presented in reference documents present in the

It is made available under a CC-BY-ND 4.0 International license .

317 literature.³³ It was also possible to verify a high detection capacity even at low 318 concentrations of genetic material since the detection limit obtained varied between \approx 2 319 and \approx 13 copies/µL of the target gene used as control.

Several studies report the growth in the prevalence of the *bla*KPC gene, with this being the most detected carbapenemase worldwide. The values found vary according to the location. The main variant of the *bla*KPC gene detected is *bla*KPC-2, with prevalence values varying from 1.2% to 51.6% among enterobacteria in studies carried out in the United States of America and China respectively.^{34, 35} This gene is found more frequently in isolates of *K. pneumoniae*, many studies report high prevalence rates in this species ranging from 17.2% to 64.6%,^{4, 35, 36, 37}

In a study conducted in an intensive care unit in the northeast region of Brazil, it was shown that of 25 isolates of *K*. pneumoniae obtained during the research, 100% exhibited the presence of the *bla*KPC gene. ³⁸

The values found in this paper for the *bla*KPC gene may reflect the fact that the primer developed detected all variants of the gene, as well as the higher rates of resistance usually found in intensive care unities (ICU).³⁹

The results found in this work are in agreement with other studies performed at the northeast of Brazil³⁸, what can represent an endemic presence of the *bla*KPC gene among *K. pneumoniae* isolates in this Brazilian region.

The *bla*TEM and *bla*SHV genes were the first ESBL identified, and together with the *bla*CTX-M subfamily of genes are considered the most prevalent ESBL's. These genes are widely distributed among enterobacteria; in a study carried out in Sudan, the *bla*TEM, *bla*CTX-M and *bla*SHV genes were identified in 86.0%, 78.0% and 28.0% respectively.⁴⁰

It is made available under a CC-BY-ND 4.0 International license .

341	In a work carried out in ICUs in Chile, it was possible to verify the presence of
342	these genes with prevalence rates of 81.0%, 84.7% and 73.0% for <i>bla</i> SHV, <i>bla</i> CTX-M-1
343	and <i>bla</i> TEM, where a higher prevalence of the <i>bla</i> SHV gene was found when compared
344	to the study carried out in Sudan. ⁴¹
345	In Brazil, it is also possible to verify the presence of high prevalence rates of
346	these genes among K. pneumoniae isolates from ICU, with studies indicating rates of
347	100%, 96% and 72% for <i>bla</i> TEM, <i>bla</i> SHV and <i>bla</i> CTX-M1 respectively. ³⁸ These results
348	agree with those evidenced in this study for the K. pneumoniae isolates tested.
349	The <i>bla</i> NDM gene is considered the second most prevalent carbapenemase
350	producing gene in the world, behind only the <i>bla</i> KPC gene. In this study, the presence
351	of the metallo beta-lactamase NDM gene was verified in (33.61%) of the isolates.
352	Similar results were evidenced in China, where the presence of this gene was verified
353	in 35.7% of 935 carbapenem-resistant enterobacteria tested. ³⁴
354	The prevalence found in this study for the <i>bla</i> NDM gene is still below what was
355	found in other studies carried out in Brazil in the states of São Paulo and Sergipe,
356	where the authors found a prevalence of 70 and 50% respectively in K. pneumoniae
357	isolates. ^{42,43}

Regarding oxacillinases, a low prevalence of the *bla*OXA-48*like* gene was observed (3.28%). This gene may be present in all *Enterobacteriaceae*; however, it is more prevalent in strains of *K. pneumoniae*.²¹

361 The values found in the literature for the presence of this gene in 362 *Enterobacteriaceae* are very divergent, with marked variations related to the location of 363 the analysis, these values vary from 7.3% in China to 83.3% in Morocco.^{34, 44} In a study 364 conducted in Brazil where 4,451 isolates of *Enterobacteriaceae* were analyzed, the

It is made available under a CC-BY-ND 4.0 International license .

*bla*OXA-48*like* gene was detected in only 2.5% of the isolates tested.⁴⁵ In this way, the
result obtained is compatible with what was previously identified in Brazil, and close
to what is seen in China.

368 The presence of variants of the blaOXA gene (bla-OXA-51like (15.57%), blaOXA-369 24/40like (11.48%) and blaOXA-23like (28.69%)) was also observed in the isolates tested, 370 these genes were long considered exclusive to strains of Acinetobacter baumannii, 371 however studies have demonstrated the presence of these genes in other 372 Enterobacteriaceae, including K. pneumoniae.⁴⁶ Results regarding the prevalence of these 373 genes in strains of K. pneumoniae are still scarce, however, in a study conducted in 374 Bahrain in the Persian Gulf, the blaOXA-51 and blaOXA-23 genes were identified 375 respectively in 45.8% and 41.6%. % of K. pneumoniae isolates analyzed.⁴⁷

376 It is believed that many of the beta-lactamases that today can be found 377 contained in mobile genetic elements had their origin in chromosomes of other 378 bacteria, as occurred with the SHV type variants that derived from the K. pneumoniae 379 chromosomal SHV-1, and the CTX-M type variants that appear to have originated from 380 the chromosomal CTX-M of *Kluyvera* spp²¹. This change in the presentation of these 381 genes, from chromosomal to mobile elements, may explain the appearance of genes 382 such as chromosomal *bla*OXA present in *A. baumannii* strains on plasmids widespread 383 in other species.

It was possible to verify the presence of isolates presenting multiple genes coding for beta-lactamases, from 3 to 12 of the genes analyzed. Studies point to a high prevalence among *Enterobacteriaceae* of the accumulation of genes from the *bla* family, mainly genes belonging to ESBL, OXA beta-lactamases and carbapenemases such as *bla*KPC and *bla*NDM. This phenomenon is more evident in hospital environments

It is made available under a CC-BY-ND 4.0 International license .

389 where selective pressure favors microorganisms carrying resistance genes and where

390 there is a high rate of sharing of these genes.^{48,49}

391 Investigations into metabolomic modulation in K. pneumoniae have 392 demonstrated a promising area for understanding resistance to antimicrobial agents, 393 developing new therapies, and for studying bacterial virulence. For example, 394 significant inhibition of the pentose phosphate pathway, citrate cycle, amino acid and 395 nucleotide metabolism was observed to be beneficial during treatment of MDR K. 396 pneumoniae using the bacteriophage-polymyxin combination, showing the potential for 397 new therapeutic targets and pathways metabolic processes to improve the effectiveness 398 of treatment with available antimicrobial agents.^{50,51}

399 This study is in accordance with others that highlighted the importance of the 400 pentose phosphate pathway in MDR K. pneumoniae strains.⁵⁰ This finding was present 401 in both media, supernatant and intracellular in MDR isolates, compared with K. 402 *pneumoniae* isolates susceptible to antimicrobial agents. The significant presence of the 403 metabolic N-fructosyl isoleucine (C12H23NO7; MW: 293.316) in the supernatant and 404 intracellular media of K. pneumoniae MDR indicates the expression of the fructose 405 degradation enzyme gene (frwC; fructose-specific phosphotransferase system), which is 406 involved in regulating bacterial growth, virulence and overcoming colonization resistance due to the use of alternative carbon source from fructose.^{52, 53} 407

408 Metabolomics has proven to be a promising approach in the study of 409 antimicrobial resistance. Its use allows for the comprehensive investigation of 410 metabolic changes associates with different resistance mechanisms, such as alternative 411 energy-obtaining pathways, modifications that alter the cell wall, communication

It is made available under a CC-BY-ND 4.0 International license .

412 between bacterial cells, and changes in the colonization capacity of these
413 microorganisms.^{54, 55}

The identification of these metabolic differences plays an important role in the Discovery of new therapeutic targets and strategies for investigating the reversal of resistance in these pathogens.⁵⁵⁻⁵⁷ The combination of genetic and metabolomic techniques therefore contributes to a comprehensive view of resistance mechanisms in bacteria. ^{56,57}

The presence of N-fructosyl isoleucine in resistant strains, and the metabolic benefit that its presence appears to generate in increasing colonization capacity, together with the selective pressure found in ICU environments due to the constant use of antimicrobials may be related to the high rates of resistant isolates disseminated among patients in this environment.

424 The metabolic evaluation in turn points to a metabolic advantage in resistant 425 strains compared to sensitive ones, which goes beyond the resistance capacity itself.⁵⁸

426 This study has some limitations, such as the exploration of only *bla* family 427 genes, limiting a broader understanding of resistance mechanisms to antimicrobial 428 agents. On the other hand, it presents a broad methodology for exploring the 429 important bla family genes most associated with resistance to beta-lactams in K. 430 pneumonia. The metabolic findings showed a specific indication that suggests an 431 association with virulence and better proteomic studies will be necessary to associate 432 with potential mechanisms of resistance to antimicrobial agents. Furthermore, 433 additional preclinical studies will be necessary to determine and more specifically 434 validate the virulence associated with the pentose phosphate pathway in K. 435 pneumoniae.

It is made available under a CC-BY-ND 4.0 International license .

436

437

438 CONCLUSIONS

439	The results of this work show the high prevalence of resistance to antimicrobial
440	agents in isolates of K. pneumoniae within the hospital environment, and that this
441	phenotypic pattern exhibited a great concern as it limits the therapeutic options
442	available, directly implicating the patient's prognosis.
443	The assays developed were within the quality criteria for qPCR reactions using
444	SYBR Green master mix and were efficient in detecting the beta-lactams resistance
445	genes from the <i>bla</i> family evaluated in this study. The genotypes of the <i>bla</i> genes
446	obtained are relevant and worrying for the local hospital scenario, and compatible with

447 the identified phenotypic profile.

448 The identification of the metabolic N-fructosyl isoleucine in the supernatant and intracellular media of K. pneumoniae MDR indicates the expression of the fructose 449 450 degradation enzyme gene, which is involved in regulating bacterial growth, virulence and overcoming resistance to colonization due to the use of an alternative carbon 451 source from fructose. 452

453 MATERIALS AND METHODS

454 Obtaining bacterial isolates and identification. For the following study, samples were collected as part of the clinical investigation of patients admitted to the 455 456 ICU of a tertiary care health unit in the city of Fortaleza-CE. Were included in the work 457 those microorganisms that were identified as gram-negative bacteria, resistant to two

It is made available under a CC-BY-ND 4.0 International license .

458 or more groups of antimicrobial agents, including subclasses of β-lactams,
459 fluoroquinolones and aminoglycosides.

The bacterial isolates were identified and tested for their susceptibility to antimicrobials using the automated VITEK® 2 Compact method (BioMérieux, Marcy l'Etoile, France), according to the manufacturer's recommendations. Minimum inhibitory concentrations were interpreted according to the Clinical and Laboratory Standards Institute (CLSI). For quality control of sensitivity tests, strains from the American Type Culture Collection (ATCC) were used. Specimens that had a resistance profile that fit the research objectives were included in the study.

467 Extraction of bacterial DNA. To extract the genetic material, the Wizard
468 Genomic DNA Purification extraction and purification kit (Promega, Madison, USA)
469 was used, according to the manufacturer's recommendations.

470 After extraction, all samples were then quantified by spectrophotometry using
471 the NanoDropTM 2000 (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and
472 stored in a -80°C freezer until used in the experiments.

473 Selection of genes used in the study and obtaining FASTA sequences. For 474 greater coverage of the genetic profile of resistance to β-lactams in gram-negatives, 475 genes with relevant prevalence epidemiology, belonging to the *bla* gene family, were 476 part of the study, and these included the genes: *blaSHV*, *blaTEM*, *blaNDM*, *blaKPC*, 477 *blaGES*, *blaCTX-M* and *blaOXA*. The sequences used were obtained through the 478 Comprehensive Antibiotic Resistance Database (CARD) and National Center for 479 Biotechnology information (NCBI) platforms, which compiles and organizes the

It is made available under a CC-BY-ND 4.0 International license .

480 resistance gene sequences available in GenBanck, the list of identifiable sequences is

481 available in the supplementary material Text S1.

Primer design. To design the primers, all variant sequences of each gene included in the study available on the CARD and NCBI platforms were gathered, the sequences were aligned using the Clustal Omega software, and the alignments were analyzed using the SnapGene software.

486 Consensus regions with homology ≥95% were selected and these were used to
487 design the primers using the Primer Blast platform from the National Center for
488 Biotechnology and Information (NCBI, USA). The consensus sequences obtained is
489 available in the supplementary material Text S2.

490 Genes with few conserved regions, for which it was not possible to obtain
491 consensus sequences with homology ≥95%, were separated into clades, and primers
492 were then designed for the sequences by phylogenetic grouping, complying with a
493 minimum of 95% similarity.

In silico validation of the developed primers. All primers developed were
validated *in silico* regarding their specificity, structure, formation of primer-dimers and
hairpins using the Primer-BLAST® (NCBI, USA) and Sequence Manipulation Suite
(SMS): PCR Primer Stats platforms.

498 **Testing, optimization, and standardization of primers.** The reactions were 499 standardized with the use of positive controls developed in-house, through 500 amplification of genetic material, isolation, and purification of amplicons, originating 501 from isolates phenotypically resistant to beta-lactams, and negative control (water 502 DNase/RNase free). They were carried out using a CYBR Green master mix (Promega,

It is made available under a CC-BY-ND 4.0 International license .

503 Madison, USA), the initial results were evaluated regarding the melting temperature

504 (Tm), to confirm the specificity of the amplicons.

505 To determine the most efficient qPCR conditions, to reduce the existence of 506 non-specificity and facilitate the interpretation of the results, the concentration gradient 507 and annealing temperature (Ta) of the primers were performed. The qPCR reaction 508 conditions included a hot start step at 95°C for 2 minutes, followed by 35 cycles 509 consisting of a denaturation step for 15 seconds at 95°C, and an annealing/extension 510 step for 1 minute at Ta. specific to each primer, all reactions went through a final 511 melting curve step, with a temperature variation of 60 to 95°C with an increase of 512 0.05°C/sec.

A 9-point efficiency curve was performed with a dilution factor of 1:8, for each primer developed, with concentrations ranging from $\approx 27,438,596$ to ≈ 2 (copies/µL), through this procedure it was possible to determine the values of threshold, evaluate the efficiency (%), the correlation coefficient (R²) and the limit of detection of each primer.

518 **Detection of resistance-related genes by molecular biology.** The *K. pneumoniae* 519 isolates obtained in the study were tested against the developed primers. Melting 520 curve analysis of all reactions was used to evaluate the specificity of the results of the 521 isolates in comparison to the specific melting temperature (Tm) of the positive control.

522 **Preparation of** *K.* **pneumoniae samples for metabolomic evaluation.** Isolates 523 of *K. pneumoniae* susceptible and multidrug resistant to antimicrobial agents obtained 524 in this work were submitted for metabolomic analysis. For this experiment, seven 525 samples of the culture supernatant were designed: one sample of the culture medium, 526 two samples of the culture supernatant of susceptible *K. pneumoniae* (biological

It is made available under a CC-BY-ND 4.0 International license .

replicates), four samples of the culture supernatant of multidrug-resistant *K*. *pneumoniae* (MDR) for untargeted metabolomics determination and analysis. Samples of the intracellular medium of the *K. pneumoniae* culture, two samples of susceptible *K*. *pneumoniae* (biological replicates) and four samples of MDR *K. pneumoniae* were also used for untargeted metabolomic analysis. Technical replicates were performed for susceptible media and samples to allow for a pilot statistical comparison.

533 Methodology for extracting K. pneumoniae culture supernatant. To 200 µL of 534 K. pneumoniae culture medium or control medium, 800 µL of 80% methanol was added 535 at -20 °C. The samples were vortexed and incubated at -20°C for 2 hours for protein 536 precipitation. The samples were centrifuged for 10 min at 4°C at 10,000 g (Benchtop 537 refrigerated centrifuge 10k RPM Eppendorf) and the supernatants were transferred to 538 new tubes. The samples were dried under vacuum (Speed Vac Thermo fisher) for 539 approximately 4-5 hours. Dried samples were redissolved in 100 μ L of 0.1% formic 540 acid in water containing Metabolomics QReSS labeled heavy standards diluted 100X. 541 (https://www.isotope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). А 542 quality control (QC) was done, combining 10 μ L of each sample. After the QC test in 543 the mass spectrometer, the samples were diluted 10x to be analyzed. The injection 544 volume of each sample was 10 µL per ionization mode.

545 Methodology for extractions from the intracellular medium of *K. pneumoniae* 546 culture. To each tube, 750 μ L of cold chloroform:methanol (2:1) mixture at -20 °C was 547 added, vortexed and transferred to tubes reinforced with a ball beater. Cells were 548 disrupted in a bead beater with steel balls for 3 min at an intensity of 5 (Bead Ruptor 549 Elite Omni International Material). The tubes were shaken vigorously for 30 min at 4°C 550 in a temperature-controlled thermal shaker (Thermomixer Eppendorf). 400 μ L of water

It is made available under a CC-BY-ND 4.0 International license .

551	was added, shaken vigorously, and centrifuged for 10 min at 10,000 rpm (Benchtop
552	refrigerated centrifuge 10k RPM Eppendorf) for phase separation. The upper
553	aqueous/methanolic phase was saved as a mixture of soluble metabolites and
554	transferred to Eppendorf tubes. Soluble metabolites were dried under vacuum for 3-4 h
555	(Speed Vac Thermo Fisher). Before running, samples were reconstituted in 100 μL of
556	0.1% formic acid in water containing 100X diluted Metabolomics QReSS labeled heavy
557	standards
558	(https://www.isotope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). The

(https://www.isotope.com/userfiles/files/assetLibrary/MET_RSCH_QReSS.pdf). The
QC sample was prepared with 10 μL of each sample. The injection volume of each
sample was 10 μL.

561 Analysis by Ultra Performance Liquid Chromatography Coupled to Tandem 562 Mass Spectrometry (UPLC-MS/MS) of metabolites. MS data were acquired on the 563 Orbitrap IDX spectrometer (Thermo) connected to the Vanguish UPLC system. Soluble 564 metabolites were separated using a Waters BEH C18 column (100 x 2.1 mm, 1.9 µm) 565 operated at 30 °C and a flow rate of 250 µL/min. Mobile phase A was 0.1% formic acid 566 in water and mobile phase B was 0.1% formic acid in 90% methanol. Bulk scan range: 567 67-1000 at 120,000 resolutions with 0.6 sec scan range. The 10 most intense ions in each 568 full scan were selected for fragmentation and MS2 spectra were acquired at a 569 resolution of 30,000 and scaled collision dissociation fragmentation energy of 25, 30, 35 570 was used.

571 UPLC gradient. The total time used in the UPLC gradient runs was 15 minutes.
572 The flow used was 0.250 mL/min and the following gradient in the percentage of
573 mobile phase B was 50% at 8 min, 98% at 9 min. maintaining until a time of 13 min.,
574 ending with 0% between a time of 13.1 – 15 min.

It is made available under a CC-BY-ND 4.0 International license .

575 Verification settings in the mass spectrum. The configurations used in the verification through the mass spectrum were orbit trap of the mass spectrum in the 576 577 master scan, with an orbitrap detector with a resolution of 120,000. We used 578 quadrupole isolation with a scanning range between 67-1000 m/z, using the frequency 579 lens at 60%. The automatic gain control target was customized and normalized to 25%. 580 The maximum injection time mode has been customized with a maximum injection 581 time of 50 ms. MIcroscans of 1 and profile with positive polarity. Font fragmentation 582 has been disabled.

583 Data acquisition, metabolic identification, and data analysis. Once the data 584 was acquired, the samples were analyzed using the open-source software MS-DIAL. 585 More details about the software be obtained here: can http://prime.psc.riken.jp/compms/msdial/main.html.^{59,60} Three blank samples were 586 587 included in the analysis to identify background ions and remove them later. Samples 588 acquired using MS1 full scan used for quantification and data-dependent acquisition 589 (DDA) mode were used for spectral identification of metabolites. Tolerance MS1 was 590 set to 0.01 Da and MS2 set to 0.025 Da. For peak harvesting, the mass slice width was 591 set to 0.1. For peak alignment, the maximum retention time tolerance was set at 0.5 592 min, the MS1 tolerance was set at 0.01. Peaks were identified by searching MS2 spectra 593 in the public MS-DIAL database downloaded in January 2023 (324,191 records for 594 positive mode and 64,669 entries for negative mode) using a mass tolerance of 0.01 Da 595 for MS1 and 0.05 Gives to MSMS with an identification cutoff point of 80% 596 http://prime.psc.riken.jp/compms/msdial/main.html#MSP. Additionally, peaks were 597 also searched against the core Biomolecular Analysis Facility's internal IROA library 598 (both positive and negative mode) with a mass tolerance of 0.02 and identification

It is made available under a CC-BY-ND 4.0 International license .

- 599 cutoff of 85%. The data was manually inspected and identifications without MS2 were
- 600 filtered, except for identifications of the IROA molecule.
- 601
- 602
- 603
- 604 Supplementary Materials: The following supporting information: Figures S1-S7; Text
 605 S1; Text S2.
- 606 Figure supplement legend:

Figure S1 – Primer's specificity evaluation through Melting curve: (A) SHV, (B)
KPC, (C) NDM, (D) TEM, (E) GES, (F) OXA-23*like*, (G) OXA-24/40like, (H) OXA-48like,
(I) OXA-51like, (J) CTX-M 1.1*like*, (K) CTX-M 1.2*like*, (L) CTX-M 2*like*, (M) CTX-M 8*like* e
(N) CTX-M 9*like*.

Figure S2 - Plot analysis of the 25 main metabolites from the supernatant of susceptible *K. pneumoniae* in general without separation by up- or down-regulation of the analytes. Note that in the supernatant of *K. pneumoniae* compared to the culture media, metabolites related to the synthesis of nitrogenous bases, protein synthesis and energy supply to the bacterial cell are significantly increased.

Figure S3 - Plot of the analysis of the 25 main metabolites from the supernatant
of susceptible *K. pneumoniae*, separated because they were up-regulated in relation to
the control culture media.

Figure S4 - Plot of the analysis of the 25 main metabolites from the supernatant
of susceptible *K. pneumoniae*, separated because they were down-regulated in relation
to the control culture media.

It is made available under a CC-BY-ND 4.0 International license .

622	Figure S5 - Plot of the analyzes of the 25 main metabolites from the supernatant
623	of Multidrug-Resistant (MDR) K. pneumoniae in general without separation by up- or
624	down-regulation in the analytes. Note that in the intracellular media of K. pneumoniae
625	compared to the culture medium, metabolites related to the synthesis of nitrogenous
626	bases, protein synthesis and energy supply to the bacterial cell are significantly
627	increased.

Figure S6 - Plot of the analysis of the 25 main metabolites from the supernatant
of *K. pneumoniae* MDR, separated by being up-regulated in relation to the control
culture media.

Figure S7 - Plot d of the analysis of the 25 main metabolites from the supernatant of *K. pneumoniae* MDR, separated because they were down-regulated in relation to the control culture media.

634

635 AUTHOR INFORMATION

636 **Corresponding Authors:**

637 Aldo A.M. Lima - Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara,

638 Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department

639 of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.

640 https://orcid.org/0000-0002-0299-1747

641 Email: <u>alima@ufc.br</u>

642 José Kleybson de Sousa – Department of Pediatrics Gastroenterology, UVA Hospital,

643 University of Virginia, Charlottesville, Virginia 22903, United States;

644 <u>https://orcid.org/0000-0003-3512-484X</u>

It is made available under a CC-BY-ND 4.0 International license .

645 Email: <u>ztx7ex@virginia.edu;</u>

646

647 Authors

- 648 Lavouisier F.B. Nogueira Institute of Biomedicine, Faculty of Medicine, Federal University
- 649 of Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program,
- 650 Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
- 651 https://orcid.org/0000-0002-5008-8181
- 652 Marília S. Maia Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara,
- 653 Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department
- 654 of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
- 655 https://orcid.org/0000-0002-7005-7841
- 656 Marco A.F Clementino Institute of Biomedicine, Faculty of Medicine, Federal University of
- 657 Ceara, Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program,
- 658 Department of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
- 659 https://orcid.org/0000-0002-0628-8047
- 660 Ila F.N. Lima Hospital Universitário Walter Cantídio, Federal University of Ceara,
 661 Fortaleza-Ceara 60430-270, Brazil.
- 662 Jorge L.N. Rodrigues Hospital Universitário Walter Cantídio, Federal University of Ceara,
- 663 Fortaleza-Ceara 60430-270, Brazil.
- 664 Luciana V.C. Fragoso Hospital Universitário Walter Cantídio, Federal University of Ceara,
- 665 Fortaleza-Ceara 60430-270, Brazil.

It is made available under a CC-BY-ND 4.0 International license .

- 666 Glairta S. Costa Hospital Universitário Walter Cantídio, Federal University of Ceara,
- 667 Fortaleza-Ceara 60430-270, Brazil.
- 668 Jose Q.S. Filho Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara,
- 669 Fortaleza-Ceara 60430-270, Brazil. <u>https://orcid.org/0000-0002-9619-4553</u>
- 670 Alexandre Havt Institute of Biomedicine, Faculty of Medicine, Federal University of Ceara,
- 671 Fortaleza-Ceara 60430-270, Brazil. Postgraduate Medical Microbiology Program, Department
- 672 of Medicine, Federal University of Ceara, Fortaleza-Ceara 60430-270, Brazil.
- 673 <u>https://orcid.org/0000-0002-4546-2976</u>
- 674 Deiziane V.S. Costa Infectious Diseases and International Health, University of Virginia,
- 675 Charlottesville, VA 22908. <u>https://orcid.org/0000-0001-6402-8908</u>
- 676 Lyvia M.V.C. Magalhães Institute of Biomedicine, Faculty of Medicine, Federal University
- 677 of Ceara, Fortaleza-Ceara 60430-270, Brazil. <u>https://orcid.org/0000-0001-6990-4903</u>
- 678 Dilza Silva Biomolecular Analysis Facility, School of Medicine, University of Virginia,
- 679 Charlottesville, VA 22908. <u>https://orcid.org/0000-0002-6519-346X</u>
- 680 Nicholas E. Sherman Biomolecular Analysis Facility, School of Medicine, University of
- 681 Virginia, Charlottesville, VA 22908. <u>https://orcid.org/0000-0003-3206-3113</u>

682

683 Author Contributions:

- <u>Bibliographic review and data collection</u>, Lavouisier F.B. Nogueira, Marília S.
- 685 Maia, Marco A.F Clementino and Aldo A.M. Lima.

686	• <u>Methodology</u> , Lavouisier F.B. Nogueira, Marília S. Maia, Marco A.F								
687	Clementino, Alexandre Havt, Ila F.N. Lima, Jorge L.N. Rodrigues, Luciana V. C.								
688	Fragoso and Aldo A. M. Lima <u>.</u>								
689	• <u>Bioinformatics</u> , Lavouisier F.B. Nogueira and Marco A.F Clementino.								
690	• <u>In silico analyses</u> , Lavouisier F.B. Nogueira, Marco A.F Clementino.								
691	• In vitro validation of primers and sample testing, Lavouisier F.B. Nogueira,								
692	Marília S. Maia.								
693	• Metabolomics, Datascience and data Bank, Jose Q.S. Filho; Deiziane V.S. Costa,								
694	José K. Sousa, Lyvia M.V.C. Magalhães, Dilza Silva, Nicholas E. Sherman and								
695	Aldo A.M. Lima								
696	• Written review and editing, Lavouisier F.B. Nogueira.								
697	• <u>Supervision</u> , Alexandre Havt and Aldo A.M. Lima.								
698	• <u>Project administration</u> , Aldo A.M. Lima.								
699	• <u>Resource acquisition</u> , Aldo A.M. Lima.								
700									
701	Funding: This research was funded by CNPq (http://www.cnpq.br), grant numbers								
702	402607/2018-0 and 408549/2022-0 and FUNCAP (https://www.funcap.ce.gov.br/), grant								
703	number: OFÍCIO № 102/2021 – DINOV.								
704	Acknowledge: This work used the following equipment's (Benchtop refrigerated								
705	centrifuge 10k RPM Eppendorf; Speed Vac Thermo fisher; Bead Ruptor Elite Omni								
706	International Material; Thermomixer Eppendorf; Orbitrap IDX spectrometer (Thermo)								
707	connected to the Vanquish UPLC system) available in the Biomolecular Analysis Core								
708	Facility which is supported by the University of Virginia School of Medicine, Research								
709	Resource Identifiers (RRID):SCR_025476.								

It is made available under a CC-BY-ND 4.0 International license .

7	1	n
7	Т	υ

711	Data	Availability Statement: The data and reports relating to this study will be								
712	available via direct request via email to the corresponding author.									
713										
714	Con	flicts of Interest: The authors declare that there are no financial or personal								
715	conf	licts of interest that may have influenced the work.								
716	REF	ERENCES								
717 718	(1)	Munita, J. M.; Arias, C. A. Mechanisms of Antibiotic Resistance. Microbiol Spectr 2016, 4								
719		(2). https://doi.org/10.1128/MICROBIOLSPEC.VMBF-0016-2015.								
720	(2)	Frieri, M.; Kumar, K.; Boutin, A. Antibiotic Resistance. J Infect Public Health 2017, 10 (4),								
721		369–378. https://doi.org/10.1016/J.JIPH.2016.08.007.								
722	(3)	Holt, K. E.; Wertheim, H.; Zadoks, R. N.; Baker, S.; Whitehouse, C. A.; Dance, D.; Jenney,								
723		A.; Connor, T. R.; Hsu, L. Y.; Severin, J.; Brisse, S.; Cao, H.; Wilksch, J.; Gorrie, C.; Schultz,								
724		M. B.; Edwards, D. J.; Van Nguyen, K.; Nguyen, T. V.; Dao, T. T.; Mensink, M.; Le Minh,								
725		V.; Nhu, N. T. K.; Schultsz, C.; Kuntaman, K.; Newton, P. N.; Moore, C. E.; Strugnell, R.								
726		A.; Thomson, N. R. Genomic Analysis of Diversity, Population Structure, Virulence, and								
727		Antimicrobial Resistance in Klebsiella Pneumoniae, an Urgent Threat to Public Health.								
728		Proc Natl Acad Sci U S A 2015 , 112 (27), E3574–E3581.								
729		https://doi.org/10.1073/PNAS.1501049112/SUPPL_FILE/PNAS.1501049112.SD01.XLSX.								
730	(4)	Asri, N. A. M.; Ahmad, S.; Mohamud, R.; Hanafi, N. M.; Zaidi, N. F. M.; Irekeola, A. A.;								
731		Shueb, R. H.; Yee, L. C.; Noor, N. M.; Mustafa, F. H.; Yean, C. Y.; Yusof, N. Y. Global								
732		Prevalence of Nosocomial Multidrug-Resistant Klebsiella Pneumoniae: A Systematic								
733		Review and Meta-Analysis. <i>Antibiotics</i> 2021 , 10 (12).								

734 https://doi.org/10.3390/ANTIBIOTICS10121508.

It is made available under a CC-BY-ND 4.0 International license .

735	(5)	Sharma, A.; Thakur, A.; Thakur, N.; Kumar, V.; Chauhan, A.; Bhardwaj, N. Changing
736		Trend in the Antibiotic Resistance Pattern of Klebsiella Pneumonia Isolated From
737		Endotracheal Aspirate Samples of ICU Patients of a Tertiary Care Hospital in North
738		India. <i>Cureus</i> 2023 , 15 (3). https://doi.org/10.7759/CUREUS.36317.

739 (6) Cortés, G.; Borrell, N.; De Astorza, B.; Gómez, C.; Sauleda, J.; Albertí, S. Molecular

Analysis of the Contribution of the Capsular Polysaccharide and the Lipopolysaccharide

- 741 O Side Chain to the Virulence of Klebsiella Pneumoniae in a Murine Model of
 742 Pneumonia. *Infect Immun* 2002, 70 (5), 2583–2590. https://doi.org/10.1128/IAI.70.5.2583-
- 743 2590.2002/FORMAT/EPUB.

740

- 744 (7)Struve, C.; Bojer, M.; Krogfelt, K. A. Identification of a Conserved Chromosomal Region 745 Encoding Klebsiella Pneumoniae Type 1 and Type 3 Fimbriae and Assessment of the Role 746 Pathogenicity. Infect 2009, 5016-5024. of Fimbriae in Immun 77 (11), 747 https://doi.org/10.1128/IAI.00585-09/FORMAT/EPUB.
- Lin, C. T.; Chen, Y. C.; Jinn, T. R.; Wu, C. C.; Hong, Y. M.; Wu, W. H. Role of the CAMP-748 (8)749 Dependent Carbon Catabolite Repression in Capsular Polysaccharide Biosynthesis in 750 Klebsiella Pneumoniae. PLoS One 2013, 8 (2),e54430. 751 https://doi.org/10.1371/JOURNAL.PONE.0054430.
- 752 (9) Davies, J.; Davies, D. Origins and Evolution of Antibiotic Resistance. *Microbiol Mol Biol*753 *Rev* 2010, 74 (3), 417. https://doi.org/10.1128/MMBR.00016-10.
- 754 (10) Salipante, S. J.; Jerome, K. R. Digital PCR-An Emerging Technology with Broad
 755 Applications in Microbiology. *Clin Chem* 2020, 66 (1), 117–123.
 756 https://doi.org/10.1373/CLINCHEM.2019.304048.
- 757 (11) Fortuin, S.; Soares, N. C. The Integration of Proteomics and Metabolomics Data Paving
 758 the Way for a Better Understanding of the Mechanisms Underlying Microbial Acquired
 759 Drug Resistance. Frontiers in Medicine 2022, 9. https://doi.org/10.3389/fmed.2022.849838.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.30.23300671; this version posted September 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Zeng, C.; Tandhanskul, A.; Krungkaew, S.; Likhanapaiboon, T.; Kasayapanan, W.;

760

(12)

		U			U	-			•			
761		Yasurin, P.; Tang, J.; Phusantisampan, T.; Tawai, A. Research Progress on Using Omics										
762		Technology to	Technology to Examine the Antimicrobial Mechanisms of Natural Active Substances.									
763		Applied	Science	e	and	Engineering	Р	rogress	2024.			
764		https://doi.org/	10.14416/j.as	sep.2024	4.07.003.							
765	(13)	Bush, K.; Brad	lford, P. A.	β-Lact	tams and β-	Lactamase In	hibitors	An Over	rview. <i>Cold</i>			
766		Spring Harb Per	spect Med 2 ()16 , 6 (8	3). https://do	i.org/10.1101/0	CSHPER	SPECT.A0	025247.			
767	(14)	Ferreira, A. M.;	Martins, K.	B.; Silv	va, V. R. da; I	Mondelli, A. I	.; Cunha	, M. de L.	R. de S. da.			
768		Correlation of I	Phenotypic	Tests w	ith the Pres	ence of the Bla	Z Gene	for Detect	ion of Beta-			
769		Lactamase.	Braz	J	Microbiol	2017,	48	(1),	159–166.			
770		https://doi.org/	10.1016/J.BJ	M.2016	.10.011.							
771	(15)	Zhu I I Pan	V Gao (γγ·μ	Hou P F D	distribution of	Carban	enemases	and Efflux			

- 771 (15) Zhu, L. J.; Pan, Y.; Gao, C. Y.; Hou, P. F. Distribution of Carbapenemases and Efflux
 772 Pump in Carbapenem-Resistance Acinetobacter Baumannii. *Ann Clin Lab Sci* 2020, 50 (2).
- 773 (16) Makharita, R. R.; El-Kholy, I.; Hetta, H. F.; Abdelaziz, M. H.; Hagagy, F. I.; Ahmed, A. A.;
- Algammal, A. M. Antibiogram and Genetic Characterization of Carbapenem-Resistant
 Gram-Negative Pathogens Incriminated in Healthcare-Associated Infections. *Infect Drug*

776 *Resist* **2020**, *13*, 3991–4002. https://doi.org/10.2147/IDR.S276975.

- 777 (17) Santos, A. L.; Dos Santos, A. P.; Ito, C. R. M.; de Queiroz, P. H. P.; de Almeida, J. A.;
- Júnior, M. A. B. de C.; de Oliveira, C. Z.; Avelino, M. A. G.; Wastowski, I. J.; Gomes, G. P.
- 779 L. A.; E Souza, A. C. S.; Vasconcelos, L. S. N. de O. L.; Santos, M. de O.; da Silva, C. A.;
- 780 Carneiro, L. C. Profile of Enterobacteria Resistant to Beta-Lactams. *Antibiotics* 2020, 9 (7),
 781 1–18. https://doi.org/10.3390/ANTIBIOTICS9070410.
- 782 (18) Abdel-Rhman, S. H. Characterization of β-Lactam Resistance in K. Pneumoniae
 783 Associated with Ready-to-Eat Processed Meat in Egypt. *PLoS One* 2020, *15* (9), e0238747.
 784 https://doi.org/10.1371/JOURNAL.PONE.0238747.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.30.23300671; this version posted September 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

785	(19)	Messaoudi, A.; Mansour, W.; Jaidane, N.; Chaouch, C.; Boujaâfar, N.; Bouallègue, O.
786		Epidemiology of Resistance and Phenotypic Characterization of Carbapenem Resistance
787		Mechanisms in Klebsiella Pneumoniae Isolates at Sahloul University Hospital-Sousse,
788		Tunisia. Afr Health Sci 2019, 19 (2), 2008–2020. https://doi.org/10.4314/AHS.V19I2.24.

- 789 (20) Farhadi, M.; Ahanjan, M.; Goli, H. R.; Haghshenas, M. R.; Gholami, M. High Frequency of
- 790 Multidrug-Resistant (MDR) Klebsiella Pneumoniae Harboring Several β-Lactamase and
- 791 Integron Genes Collected from Several Hospitals in the North of Iran. *Annals of Clinical*
- 792 *Microbiology and Antimicrobials* **2021**, 20 (1). https://doi.org/10.1186/s12941-021-00476-1.
- 793 (21) Oliveira, R.; Castro, J.; Silva, S.; Oliveira, H.; Saavedra, M. J.; Azevedo, N. F.; Almeida, C.
- Exploring the Antibiotic Resistance Profile of Clinical Klebsiella Pneumoniae Isolates in
 Portugal. *Antibiotics (Basel)* 2022, *11* (11). https://doi.org/10.3390/ANTIBIOTICS11111613.
- 796 (22) Bush, K.; Bradford, P. A. Epidemiology of β-Lactamase-Producing Pathogens. *Clin* 797 *Microbiol Rev* 2020, 33 (2). https://doi.org/10.1128/CMR.00047-19.
- (23) Castanheira, M.; Simner, P. J.; Bradford, P. A. Extended-Spectrum β-Lactamases: An
 Update on Their Characteristics, Epidemiology and Detection. *JAC Antimicrob Resist* 2021,
 3 (3). https://doi.org/10.1093/JACAMR/DLAB092.
- 801 (24) Gundran, R. S.; Cardenio, P. A.; Villanueva, M. A.; Sison, F. B.; Benigno, C. C.;
 802 Kreausukon, K.; Pichpol, D.; Punyapornwithaya, V. Prevalence and Distribution of
 803 BlaCTX-M, BlaSHV, BlaTEM Genes in Extended- Spectrum β- Lactamase- Producing E.
 804 Coli Isolates from Broiler Farms in the Philippines. *BMC Vet Res* 2019, 15 (1).
 805 https://doi.org/10.1186/S12917-019-1975-9.
- 806 (25) Queiroz, J. A. da S.; Alves, L. S.; Dall'acqua, D. S. V.; Souza, L. F. B.; Faculdades
 807 Integradas Aparício Carvalho. Porto Velho, R. Brasil.; Faculdades Integradas Aparício
 808 Carvalho. Porto Velho, R. Brasil.; Fundação Oswaldo Cruz. Porto Velho, R. Brasil. / F. I.
- 809 A. Carvalho. P. V. R. Brasil.; Faculdades Integradas Aparício Carvalho. Porto Velho, R.

- 810 Brasil. Desenho e Validação de Primers In Silico Para Detecção Do Vírus Sincicial
- 811 Respiratório Humano. *Revista FIMCA* **2017**, *4* (1), 17–30.
- 812 (26) Kumar, A.; Chordia, N. In Silico PCR Primer Designing and Validation. Methods Mol Biol
- 813 **2015**, *1275*, *143–151*. https://doi.org/10.1007/978-1-4939-2365-6_10.
- 814 (27) Rodríguez, A.; Rodríguez, M.; Córdoba, J. J.; Andrade, M. J. Design of Primers and Probes
- 815 for Quantitative Real-Time PCR Methods. *Methods in Molecular Biology* **2015**, 1275, 31–56.
- 816 https://doi.org/10.1007/978-1-4939-2365-6_3.
- 817 (28) van Weezep, E.; Kooi, E. A.; van Rijn, P. A. PCR Diagnostics: In Silico Validation by an
- 818 Automated Tool Using Freely Available Software Programs. J Virol Methods 2019, 270,
- 819 106–112. https://doi.org/10.1016/J.JVIROMET.2019.05.002.
- 820 (29) Yang, J.; Kemps-Mols, B.; Spruyt-Gerritse, M.; Anholts, J.; Claas, F.; Eikmans, M. The
- Source of SYBR Green Master Mix Determines Outcome of Nucleic Acid Amplification
 Reactions. *BMC Res Notes* 2016, 9 (1), 1–10. https://doi.org/10.1186/S13104-016-20934/FIGURES/4.
- (30) Wang, Y.; Li, W.; Guo, X.; Zhang, D.; Sun, J.; Fu, Z.; Liu, G.; Li, Y.; Jiang, S. Development
 of SYBR Green I-Based Polymerase Chain Reaction for Feline Bocavirus 1 Detection. 3
- 826 Biotech 2021, 11 (2). https://doi.org/10.1007/S13205-020-02577-8.
- (31) Desriani; Azamris; Ghaissani, S. S.; Kinanti, S. R.; Warisman, M. A.; Fitria, N. Design and
 Characterization of a SYBR Green I-Based Melting Curve Method for Investigation of
 HER2I655V Polymorphism in Breast Cancer. *J Genet Eng Biotechnol* 2021, 19 (1).
 https://doi.org/10.1186/S43141-020-00108-9.
- 831 (32) Svec, D.; Tichopad, A.; Novosadova, V.; Pfaffl, M. W.; Kubista, M. How Good Is a PCR
 832 Efficiency Estimate: Recommendations for Precise and Robust QPCR Efficiency
 833 Assessments. *Biomol Detect Quantif* 2015, 3, 9–16.
- 834 https://doi.org/10.1016/J.BDQ.2015.01.005.

835	(33)	Thermo	Fisher	Scientific.	Real-Time	PCR:	Understanding	Ct	-	US.
836		https://ww	vw.therm	ofisher.com/u	s/en/home/lif	e-science	/pcr/real-time-pcr,	/real-ti	me-p	ocr-
837		learning-c	enter/real	-time-pcr-bas	ics/real-time-j	ocr-unde	rstanding-ct.html	(acces	sed	2024-
838		05-05).								

- 839 (34) Han, R.; Shi, Q.; Wu, S.; Yin, D.; Peng, M.; Dong, D.; Zheng, Y.; Guo, Y.; Zhang, R.; Hu, F.
 840 Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among
- 841 Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in
 842 China. *Front Cell Infect Microbiol* 2020, *10*, 314. https://doi.org/10.3389/FCIMB.2020.00314.
- 843 (35) Marschall, J.; Tibbetts, R. J.; Dunne, W. M.; Frye, J. G.; Fraser, V. J.; Warren, D. K. Presence
- of the KPC Carbapenemase Gene in Enterobacteriaceae Causing Bacteremia and Its
 Correlation with In Vitro Carbapenem Susceptibility. *J Clin Microbiol* 2009, 47 (1), 239.
 https://doi.org/10.1128/JCM.02123-08.
- 847 (36) Kharazmkia, A.; Amirizadeh, M.; Goudarzi, Z.; Birjandi, M.; Barfipoursalar, A.; Mir, S. 848 Prevalence of KPC-Producing Bacteria in Negative Gram of Clinical Samples Obtained 849 from Patients. 2022, 77, 103690. Annals Medicine Surgery of and 850 https://doi.org/10.1016/J.AMSU.2022.103690.
- 851 (37) Pawłowska, I.; Ziółkowski, G.; Jachowicz-Matczak, E.; Stasiowski, M.; Gajda, M.;
 852 Wójkowska-Mach, J. Colonization and Healthcare-Associated Infection of Carbapenem853 Resistant Enterobacteriaceae, Data from Polish Hospital with High Incidence of
 854 Carbapenem-Resistant Enterobacteriaceae, Does Active Target Screening Matter?
 855 *Microorganisms* 2023, 11 (2). <u>https://doi.org/10.3390/MICROORGANISMS11020437</u>.
- 856 (38) Ferreira, R. L.; da Silva, B. C. M.; Rezende, G. S.; Nakamura-Silva, R.; Pitondo-Silva, A.;
- 857 Campanini, E. B.; Brito, M. C. A.; da Silva, E. M. L.; Freire, C. C. de M.; Cunha, A. F. da;
- 858 Pranchevicius, M.-C. da S. High Prevalence of Multidrug-Resistant Klebsiella
 859 Pneumoniae Harboring Several Virulence and β-Lactamase Encoding Genes in a

- 860 Brazilian Intensive Care Unit. Frontiers in Microbiology 2019, 9.
 861 https://doi.org/10.3389/fmicb.2018.03198.
- Kernéis, S.; Lucet, J. C.; Santoro, A.; Meschiari, M. Individual and Collective Impact of
 Klebsiella Pneumoniae Carbapenemase (KPC)-Producing K. Pneumoniae in Patients
 Admitted to the ICU. *J Antimicrob Chemother* 2021, 76 (Suppl 1), I19–I26.
 https://doi.org/10.1093/JAC/DKAA494.
- 866 (40) Dirar, M. H.; Bilal, N. E.; Ibrahim, M. E.; Hamid, M. E. Prevalence of Extended-Spectrum
- β-Lactamase (ESBL) and Molecular Detection of Bla TEM, Bla SHV and Bla CTX-M
 Genotypes among Enterobacteriaceae Isolates from Patients in Khartoum, Sudan. *Pan Afr Med J* 2020, *37*, 1–11. https://doi.org/10.11604/PAMJ.2020.37.213.24988.
- 870 (41) Pavez, M.; Troncoso, C.; Osses, I.; Salazar, R.; Illesca, V.; Reydet, P.; Rodríguez, C.;
- 871 Chahin, C.; Concha, C.; Barrientos, L. High Prevalence of CTX-M-1 Group in ESBL872 Producing Enterobacteriaceae Infection in Intensive Care Units in Southern Chile. *Braz J*873 *Infect Dis* 2019, 23 (2), 102–110. https://doi.org/10.1016/J.BJID.2019.03.002.
- (42) Camargo, C. H.; Yamada, A. Y.; Souza, A. R. de; Reis, A. D.; Santos, M. B. N.; Assis, D. B.
- 875 de; Carvalho, E. de; Takagi, E. H.; Cunha, M. P. V.; Tiba-Casas, M. R. Genomic Diversity
- of NDM-Producing Klebsiella Species from Brazil, 2013–2022. Antibiotics 2022, 11 (10),
 1395.https://doi.org/10.3390/antibiotics11101395.
- (43) Vivas, R.; Dolabella, S. S.; Barbosa, A. A. T.; Jain, S. Prevalence of Klebsiella Pneumoniae
 Carbapenemase and New Delhi Metallo-Beta-Lactamase-Positive K. Pneumoniae in
 Sergipe, Brazil, and Combination Therapy as a Potential Treatment Option. *Revista da Sociedade Brasileira de Medicina Tropical* 2020, 53. https://doi.org/10.1590/0037-8682-00642020.
- 883 (44) Belouad, E. M.; Benaissa, E.; El Mrimar, N.; Bssaibis, F.; Maleb, A.; Elouennass, M.
 884 Predominance of OXA-48 Carbapenemase-Producing Enterobacterales in a Moroccan
 885 Hospital. Int J Microbiol 2023, 2023. https://doi.org/10.1155/2023/8581883.

medRxiv preprint doi: https://doi.org/10.1101/2023.12.30.23300671; this version posted September 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

- 886 (45) Magagnin, C. M.; Rozales, F. P.; Antochevis, L.; Nunes, L. S.; Martins, A. S.; Barth, A. L.;
- 887 Sampaio, J. M.; Zavascki, A. P. Dissemination of Bla OXA-370 Gene among Several
- 888 Enterobacteriaceae Species in Brazil. Eur J Clin Microbiol Infect Dis 2017, 36 (10), 1907–
- 889 1910. https://doi.org/10.1007/S10096-017-3012-X.
- 890 (46) Evans, B. A.; Amyes, S. G. B. OXA β-Lactamases. *Clin Microbiol Rev* 2014, 27 (2), 241–263.
- 891 https://doi.org/10.1128/CMR.00117-13/ASSET/DF7BB1F6-F6E8-4208-8829-

892 B01CD28A0242/ASSETS/GRAPHIC/ZCM9990924610006.JPEG.

- 893 (47) Shahid, M.; Ahmad, N.; Saeed, N. K.; Shadab, M.; Joji, R. M.; Al-Mahmeed, A.; Bindayna,
- 894 K. M.; Tabbara, K. S.; Dar, F. K. Clinical Carbapenem-Resistant Klebsiella Pneumoniae
- Isolates Simultaneously Harboring Bla NDM-1, Bla OXA Types and QnrS Genes from the
 Kingdom of Bahrain: Resistance Profile and Genetic Environment. *Front Cell Infect Microbiol* 2022, 12. https://doi.org/10.3389/FCIMB.2022.1033305.
- 898 (48) Manandhar, S.; Zellweger, R. M.; Maharjan, N.; Dongol, S.; Prajapati, K. G.; Thwaites, G.;
- 899 Basnyat, B.; Dixit, S. M.; Baker, S.; Karkey, A. A High Prevalence of Multi-Drug Resistant 900 Gram-Negative Bacilli in a Nepali Tertiary Care Hospital and Associated Widespread 901 Distribution of Extended-Spectrum Beta-Lactamase (ESBL) and Carbapenemase-902 Encoding Genes. Clin Microbiol Antimicrob 2020, 19 (1), 1–13. Ann 903 https://doi.org/10.1186/S12941-020-00390-Y/FIGURES/5.
- 904 (49) Awosile, B. B.; Agbaje, M.; Adebowale, O.; Kehinde, O.; Omoshaba, E. Beta-Lactamase
 905 Resistance Genes in Enterobacteriaceae from Nigeria. *Afr J Lab Med* 2022, *11* (1).
 906 https://doi.org/10.4102/AJLM.V11I1.1371.
- 907 (50) Han, M. L.; Nang, S. C.; Lin, Y. W.; Zhu, Y.; Yu, H. H.; Wickremasinghe, H.; Barlow, C. K.;
- 908 Creek, D. J.; Crawford, S.; Rao, G.; Dai, C.; Barr, J. J.; Chan, K.; Turner Schooley, R.;
- 909 Velkov, T.; Li, J. Comparative Metabolomics Revealed Key Pathways Associated with the
- 910 Synergistic Killing of Multidrug-Resistant Klebsiella Pneumoniae by a Bacteriophage-

- 911 Polymyxin Combination. Comput Struct Biotechnol J 2022, 20, 485–495.
- 912 https://doi.org/10.1016/J.CSBJ.2021.12.039.
- 913 (51) Kumar, A.; Singh, S.; Gupta, S. K.; Kumar, S.; Kumar, S.; Singh, R.; Thakur, L.; Kumar, M.;
- 914 Kapil, A.; Kumar, Y.; Kumar, N. Identification of Metabolite Extraction Method for
- 915 Targeted Exploration of Antimicrobial Resistance Associated Metabolites of Klebsiella
- 916 Pneumoniae. Sci Rep 2022, 12 (1). https://doi.org/10.1038/S41598-022-12153-0.
- 917 (52) Hudson, A. W.; Barnes, A. J.; Bray, A. S.; Ornelles, D. A.; Zafar, M. A. Klebsiella
- 918 Pneumoniae L-Fucose Metabolism Promotes Gastrointestinal Colonization and
 919 Modulates Its Virulence Determinants. *Infect Immun* 2022, 90 (10).
 920 https://doi.org/10.1128/IAI.00206-22.
- 921 (53) Lin, D.; Fan, J. M.; Wang, J.; Liu, L.; Xu, L.; Li, F.; Yang, J.; Li, B. The Fructose-Specific
- Phosphotransferase System of Klebsiella Pneumoniae Is Regulated by Global Regulator
 CRP and Linked to Virulence and Growth. *Infect Immun* 2018, 86 (8).
 https://doi.org/10.1128/IAI.00340-18.
- 925 (54) Aminov, R. Metabolomics in Antimicrobial Drug Discovery. *Expert Opinion on Drug* 926 *Discovery* 2022, 17 (9), 1047–1059. https://doi.org/10.1080/17460441.2022.2113774.
- (55) Kok, M.; Maton, L.; van der Peet, M.; Hankemeier, T.; van Hasselt, J. G. C. Unraveling
 Antimicrobial Resistance Using Metabolomics. *Drug Discovery Today* 2022, 27 (6), 1774–
 1783. https://doi.org/10.1016/j.drudis.2022.03.015.
- 930 (56) Soni, V.; Wang, Z.; Singh, V. Editorial: Bacterial Metabolomics Approach towards
 931 Antimicrobials and Resistance. *Frontiers in Microbiology* 2023, 14.
 932 https://doi.org/10.3389/fmicb.2023.1222594.
- 933 (57) Abril, A. G.; Quintela-Baluja, M.; Villa, T. G.; Calo-Mata, P.; Barros-Velázquez, J.; Carrera,
- M. Proteomic Characterization of Virulence Factors and Related Proteins in Enterococcus
 Strains from Dairy and Fermented Food Products. International Journal of Molecular
 Sciences 2022, 23 (18), 10971. https://doi.org/10.3390/ijms231810971.

It is made available under a CC-BY-ND 4.0 International license .

- 937 (58) Azhar, F.; Busharat, M.; Chaudhary, S. R.; Waheed, Z.; Jamil, M. Metabolomics in Drug
- 938 Discovery: Restoring Antibiotic Pipeline. Asian Pacific Journal of Tropical Biomedicine 2023,
- 939 13 (9), 378. https://doi.org/10.4103/2221-1691.385568.
- 940 (59) Tsugawa, H.; Cajka, T.; Kind, T.; Ma, Y.; Higgins, B.; Ikeda, K.; Kanazawa, M.;
 941 Vandergheynst, J.; Fiehn, O.; Arita, M. MS-DIAL: Data-Independent MS/MS
- 942 Deconvolution for Comprehensive Metabolome Analysis. *Nature Methods* 2015 12:6 2015,
- 943 12 (6), 523–526. https://doi.org/10.1038/nmeth.3393.
- 944 (60) Tsugawa, H.; Nakabayashi, R.; Mori, T.; Yamada, Y.; Takahashi, M.; Rai, A.; Sugiyama,
- 945 R.; Yamamoto, H.; Nakaya, T.; Yamazaki, M.; Kooke, R.; Bac-Molenaar, J. A.; Oztolan-
- 946 Erol, N.; Keurentjes, J. J. B.; Arita, M.; Saito, K. A Cheminformatics Approach to
- 947 Characterize Metabolomes in Stable-Isotope-Labeled Organisms. Nat Methods 2019, 16 (4),
- 948 295–298. https://doi.org/10.1038/S41592-019-0358-2.

949